Antimicrobial Resistance (AMR)

The WHO lists AMR in the top 10 global health threats but new antibiotic development is not keeping pace with the emergence of resistant pathogens. Novel ways to structure the market are being explored which incentivise developers and give healthcare systems new tools to fight AMR.

Publication

Taking STRIDES: The value of diagnostics against AMR

10 June 2025

Addressing a critical gap in AMR policy and evaluation Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to 10 million deaths annually…

A line chart ending in a paper airplane
News

OHE responds to the Trump administration’s Executive Order on Drug Prices

14 May 2025

Professor Graham Cookson responds to President Donald Trump’s Executive Order on drug prices published earlier this week.

A line chart ending in a paper airplane
Insights

R&D for new drugs to tackle AMR is a high-return investment for all EU member states

19 July 2024

Two recently-published papers predict high returns from a policy which incentivises the development of new antibiotics.

Insights

Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?

12 April 2024

The European Commission and European Parliament have set out their proposals for a reformed EU pharmaceutical legislation which could substantially change the incentive ecosystem for the first time in 20 years.

Insights

Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics

16 January 2024

Insight 3 of this series provides an exploration of revenue guarantee/subscription models and how they could be implemented in the EU.

Breaking the European Deadlock: Part 2 - Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
Insights

Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?

4 January 2024

This is part 2 of the insight series which explores how progress towards an effective pull incentive for antibiotics can be made in Europe.

Capturing the Broader Value of Antibiotics
Publication

Capturing the Broader Value of Antibiotics

23 November 2023

The value of antibiotics often extends beyond what HTA captures. The STEDI framework aims to capture that broader value and our report outlines a roadmap to realising its full potential.

Insights

OHE’s AMR consultation response

21 November 2023

This blog summarises our perspective on the recent proposals set out by NHS England to assess the value of new antibiotics via a new scoring system linked to a volume-delinked revenue guarantee payment. Key arguments outlined here were submitted to NHS England as part of OHE’s response to the consultation on proposals.